. One of the key mediators of calcium entry from the extracellular space are voltage-gated calcium channels -a family of membrane proteins that open in response to membrane depolarization to permit the influx of calcium along its electrochemical gradient. The mammalian nervous system expresses nine different types of calcium channels that have specific functions and subcellular distributions 8 , with additional functional diversity arising from alternative splicing events 9 and specific association with different types of ancillary subunits and regulatory proteins 10 . Calcium channel dysregulation has been linked to a number of disorders, including pain, Parkinson disease and epilepsy 7 . Furthermore, mutations in calcium channel genes in human patients have been associated with pathologies such as seizure disorders, migraine and ataxia 11, 12 . Consequently, calcium channels are considered important targets for therapeutic intervention.
A number of drugs that block voltage-gated calcium channels are in clinical use (TABLE 1) , with many other calcium channel blockers being in preclinical or early clinical development. This Review article highlights the role of these channels in neuronal function and assesses their growing potential as drug targets for nervous system disorders.
Subtypes and structure of calcium channels Before the advent of molecular cloning techniques, calcium channels in the heart and brain were classified based on their voltage-dependent activation into either high voltage-activated (HVA) or low voltage-activated (LVA; also known as T-type) channels 13 , with the latter requiring smaller membrane depolarizations to open. HVA channels are subdivided further based on their pharmacological and biophysical characteristics into L-, P-, Q-and R-types 14 . We now know that these different subtypes of HVA and LVA channels correspond to a total of ten different Cavα1 subunits that are encoded in the mammalian genome. Three of these Cavα1 subunits (Cav3.1, Cav3.2 and Cav3.3) comprise the family of T-type calcium channels, and their expression in the plasma membrane is sufficient to form functional channel proteins 15 . There are two major families of HVA Cavα1 subunits: the Cav1 family encodes four different types of L-type channels (Cav1.1 to Cav1.4), whereas the Cav2 family encompasses P/Q-type (Cav2.1), N-type (Cav2.2) and R-type (Cav2. 3) 7 channels, with P-and Q-type channels being distinguished by alternative splicing and channel subunit composition 16, 17 domains, each containing six transmembrane helices plus a pore loop (p-loop) motif (FIG. 1) that forms the permeation pathway of the channel and ensures selectivity for calcium ions over monovalent ions 7 . Each of the membrane domains also contains a voltage sensor motif that allows the channel to open in response to membrane depolarization 18 . The amino-and carboxy-terminal regions and the linkers between the four membrane domains face the cytoplasm and serve as important targets for second messenger regulation of channel function 7 . The majority of known drug interaction sites with voltagegated calcium channels lie either within the permeation pathway, or in channel regions that closely surround the pore of the channel, such as the fifth and sixth transmembrane helices [19] [20] [21] (FIG. 1) . All of the HVA Cavα1 isoforms require co-assembly with ancillary calcium channel subunits to obtain properly functioning channels 22 . Cavβ subunits are cytoplasmic proteins that associate with the domain I-II linker region of the Cavα1 subunit 23 . The Cavα2δ subunits undergo proteolytic cleavage into Cavα2 and Cavδ fragments that are then re-linked via disulphide bonds, with the Cavα2 portion being entirely exposed to the extracellular milieu and the Cavδ portion acting as a membrane anchor 24 . Cavβ and Cavα2δ sub units are each encoded by four different genes 7 . Their main functions are to regulate the biophysical characteristics of the channels and, more importantly, the export of the channel complex from the endoplasmic reticulum and the stability of the channel in the plasma membrane 25, 26 . Some HVA calcium channels also contain a Cavγ sub unit (most notably the skeletal muscle L-type channels), a transmembrane protein encoded by as many as eight different genes and with poorly understood function 27 . Each of the major calcium channel subunits is known to undergo alternative splicing 28 . Between the various splice isoforms and possible combinations of Cavα1, Cavβ and Cavα2δ subunits, a vast number of different calcium channels with a wide spectrum of functional and pharmacological properties (and potentially specific physiological functions) can be generated. This is a particularly important consideration during the development of calcium channel therapeutics, and it often relies on the heterologous expression of a specific combination of calcium channel subunits in a host cell line. 
Phenylalkylamines
A specific class of small organic molecules that block calcium channels.
Key nervous system functions of calcium channels So why do vertebrates need so many types of calcium channels? Part of the answer may lie in the notion that different calcium channel subtypes fulfil specific physiological roles, and different variants of the same calcium channel subtype may serve as a fine-tuning mechanism not only because of their particular biophysical characteristics but also because of their differential regulation. The nervous system expresses nine of the ten major calcium channel isoforms, with the skeletal-musclespecific Cav1.1 channels being the only isoforms that are absent 29 . Different calcium channel isoforms often support multiple physiological roles, and those that are particularly pertinent are discussed here. Cav1.2 channels are expressed in most types of neurons. They are often localized on cell bodies and at dendritic regions 30 , and are thought to be important for the activation of calcium-dependent enzymes 31 , the activation of calciumactivated potassium channels 32 and the initiation of calcium-dependent gene transcription events 4 . Cav1.3 channels show a similar subcellular distribution to that observed with Cav1.2 (REF. 30 ). As well as contributing to postsynaptic activity, these channels are expressed at ribbon synapses of cochlear hair cells where they have a critical role in auditory transmission 33 . Indeed, mice lacking Cav1.3 channels are deaf, as are human patients with null mutations in the Cav1.3-encoding gene CACNA1D 34, 35 . Cav1.4 channels are predominantly expressed in rod photoreceptors where they control glutamate release from ribbon synapses. Consequently, Cav1.4-null mice are blind 36 and loss of Cav1.4 expression in humans gives rise to night blindness 37 . Cav2.1 and Cav2.2 channels are expressed at presynaptic nerve terminals where they are closely associated with the neurotransmitter release machinery 3, 38 . Some synapses are designed to accommodate specific complements of each of these two channel subtypes 39 , whereas others such as primary afferent nerve terminals in the spinal dorsal horn almost exclusively express Cav2.2 channels. However, these two channel subtypes are not created equally. Whereas Cav2.2-null mice are viable and display hyposensitivity to pain 40 , Cav2.1-null mice experience seizures and cerebellar ataxia 41 . This suggests that Cav2.1 channels may have a key role besides neurotransmitter release; indeed, Cav2.1 channels have been associated with gene transcription of synaptic proteins such as syntaxin 1A 42 . In humans, gain-of-function mutations in Cav2.1 channels can give rise to familial hemiplegic migraine 43 , whereas loss-of-function mutations or polyglutamine expansions in the Cav2.1 C-terminal lead to conditions such as episodic ataxia type II 44 and spinocerebellar ataxia 6 (REF. 45 ), respectively. Conversely, mutations in Cav2.2 have been associated with myoclonus dystonia-like syndrome, which, interestingly, is accompanied by cardiac arrhythmias, perhaps owing to the role of N-type channels in the sympathetic nervous system 46 . Cav2.3 channels are thought to contribute to neurotransmitter release at a subset of central nervous system (CNS) synapses 47, 48 , as well as helping to regulate neuronal excitability. Consequently, Cav2.3-null mice are resistant to certain types of pharmacologically induced seizures 49 . The three members of the Cav3 channel family have important roles in regulating neuronal firing, which is closely linked to their specific gating characteristics 1, 50 . Their low threshold of voltage activation, coupled with their tonic inactivation at typical resting membrane potential, underlies the rebound bursting phenomenon seen in many types of neurons 51 . In this context, it is important to note that different types of Cav3 channels differentially regulate neuronal firing behaviour 51 , and this diversity is further increased by the existence of different Cav3 splice variants 52 . Finally, there is recent evidence that Cav3 channels can partake in low-threshold exocytosis, perhaps owing to their interactions with synaptic proteins such as syntaxin 1A 53 . Discussed above are just some of the most important physiological roles of these various calcium channel subtypes, and this is by no means a comprehensive account of all calcium channel functions in the nervous system. A recent review 7 on this topic provides a more in-depth discussion. This high-level summary does, however, provide appropriate context and background for the ensuing sections in this article, such as the potential of these channels as established and prospective drug targets.
Identifying new calcium channel therapeutics Fifty years ago, research on the effects of verapamil and prenylamine on excitation-contraction coupling led to the discovery of several classes of calcium blockers (originally termed calcium antagonists) 54 . Much of the initial work on these agents focused on L-type calcium channels and revealed that these channels have multiple drug interaction sites for compound classes such as dihydropyridines, phenylalkylamines and benzothiazepines 55 . As these drug interaction sites are non-competitively coupled, this enabled the use of high-throughput radioligand displacement assays to identify new compounds The transmembrane topology of the pore-forming Cavα1 subunit with its four major transmembrane domains (I-IV) is shown, each of which contains six membrane-spanning helices (termed S1-S6), as well as a re-entrant pore loop. Blockers of N-type, T-type and L-type channels are labelled, in red, blue, and green, respectively. Sites of drug interactions are shown. Note that the transmembrane domain IIIS6 and IVS6 regions are hotspots for drug interactions. BZT, benzothiazepine; DHP, dihydropyridine; PAA, phenylalkylamine.
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A process by which an ion-channel-blocking drug becomes more effective during repetitive activation of the channel.
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Pregabalin
that interacted with these channels 56 . These early studies involved native channel complexes from muscle or brain tissue 57 . The cloning of various calcium channel isoforms allowed the generation of stable cell lines that expressed one specific calcium channel subtype and that could be loaded with a calcium indicator dye 58, 59 . Membrane depolarization induced by potassium chloride (KCl) leads to channel opening, and the effects of compounds on the associated rise in calcium fluorescence can be used to determine their ability to block the channels 58, 59 . Automation of this assay allows the high-throughput screening of large compound libraries in a short time frame. Moreover, unlike the early radioligand studies, this approach is applicable to all major calcium channel isoforms and does not require the availability of tritiated drug compounds 60 .
There is a drawback, however, in the use of a single KCl depolarization, as this approach cannot easily identify compounds with strong use-dependence 61 , which is a desirable quality in compounds such as anti-arrhythmics and anticonvulsants. As many use-dependent compounds interact preferentially with inactivated channels, one way to use fluorescence assays to identify such types of blockers is to regulate the membrane potential of the cells by bathing them in slightly elevated KCl levels before applying a larger KCl depolarization that opens the channels 62, 63 . The development of high-throughput automated patch clamp systems has greatly facilitated the identification of drug compounds with specific kinetic properties 61, 64 ; however, this additional information comes at the expense of throughput.
Techniques such as photoaffinity labelling 65 , coupled with site-directed mutagenesis, have been used successfully to identify major drug interaction sites on L-type calcium channels at the single amino acid level (FIG. 1) . In some cases, knowledge of drug interactions with other classes of ion channels (such as sodium channels) has been used to identify drug interaction sites on voltage-gated calcium channels, such as T-type channels. For example, key amino acid residues that comprise the local anaesthetic interaction site in sodium channels are conserved in T-type calcium channels, and mutagenesis of these residues reduces the interaction of these channels with local anaesthetic-like compounds 19 . Curiously, the S6 regions in domains III and IV of the Cavα1 subunit appear to be hotspots for drug inter action sites in both L-type and T-type channels (FIG. 1) , perhaps because these channel structures are linked to the inactivation-gating machinery and line the inner vestibule of the channel pore 66 . When coupled with homology modelling 67 , such knowledge of the molecular makeup of drug interaction sites could potentially provide important insights into drug structure requirements for calcium channel inhibition and thus enable a rational approach towards drug design 68 . One of the challenges in designing and developing small organic calcium channel blockers is the relatively high sequence conservation among different members of the calcium channel family and sequence similarities to other members of the voltage-gated ion channel superfamily 8 . This makes it very difficult to identify compounds with high affinity and high selectivity for one particular calcium channel target. Indeed, several dihydropyridines (a class of compounds commonly thought of as being selective for L-type channels) have been shown to block other calcium channel subtypes such as T-type and N-type channels, in some cases even preferentially over L-type channels [69] [70] [71] . Despite decades of drug discovery efforts, only a few bona fide calcium channel therapeutics other than di hydro pyridines have entered the clinic. This underscores the immense challenge in finding compounds that: have high affinity; have high target selectivity (especially over HERG channels); effectively cross the blood-brain barrier; have the appropriate physicochemical properties; are not rapidly metabolized; and are non-toxic. The ensuing sections provide an overview of the therapeutic potential of calcium channel blockers in various nervous system disorders and a summary of existing drugs targeting calcium channels (TABLE 1) , as well as compounds that are currently in the drug discovery pipeline.
Calcium channel inhibitors as pain therapeutics
Pain stimuli are detected by peripheral nociceptors that innervate the skin and organ tissues. Action potentials then propagate along the primary afferent fibre to synaptic nerve terminals in the spinal dorsal horn, where excitatory synaptic transmission then activates neurons that project to higher brain centres where pain is perceived 72 (FIG. 2) . Voltage-gated calcium channels are known to factor prominently in this afferent pathway in two principal ways 73 . Cav3.2 T-type calcium channels are important regulators of afferent fibre excitability, whereas Cav2.2 and, to a lesser extent, Cav3.2 channels both contribute to neurotransmission at dorsal horn synapses 74 (FIG. 2) . Both calcium channel subtypes are upregulated under chronic pain conditions [75] [76] [77] ; conversely, inhibiting Cav2.2 and/or Cav3.2 channel activity in rodents has been shown to mediate analgesia 74 . For therapeutic purposes, Cav2.2 channels can be targeted in multiple ways. First, Cav2.2 channels are under the powerful control of several G protein-coupled receptors, including GABA B (γ-aminobutyric acid, type B) receptors and various members of the opioid receptor family 78 . Indeed, the clinically used μ-opioid receptor agonist morphine inhibits Cav2.2 channel activity and thus neurotransmitter release from primary afferent neurons 79 . However, although it is a potent analgesic, morphine has numerous side effects such as respiratory depression and constipation 80 . Therefore, receptorindependent means of inhibiting Cav2.2 channels are desirable. The gabapentinoids gabapentin (Neurontin; Pfizer) and pregabalin (Lyrica; Pfizer) inhibit synaptic transmission mediated by the Cav2.2 channel through a very different mechanism that involves interactions with the Cavα2δ subunit. These subunits are upregulated in chronic pain states 81 , leading to increased Cav2.2 cell surface expression. Treatment with gabapentinoids interferes with Cavα2δ function, leading to a reduced Cav2.2 calcium channel density in the presynaptic plasma membrane [82] [83] [84] . Despite their overall moderate 
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efficacy, these compounds are important therapeutic choices for treating neuropathic pain and have become blockbuster drugs 85 . A direct inhibitor of Cav2.2 calcium channel activity is also currently used in the clinic. Ziconotide (Prialt; Elan) is a synthetic version of ω-conotoxin MVIIA, a 26-amino-acid peptide isolated from the venom of the Conus magus fish-hunting snail. Ziconotide is a highly selective pore blocker of Cav2.2 calcium channels, and when delivered intrathecally (this peptide does not cross the blood-brain barrier) it mediates analgesia [86] [87] [88] . Besides the requirement for delivery via an implanted minipump and its limited indication for drug-resistant cancer pain, it also suffers from a narrow therapeutic window and thus has a variety of potential side effects that include memory loss and unruly behaviour 87, [89] [90] [91] . As a physical blocker of the Cav2.2 channel pore, ziconotide does not exhibit use-dependent blocking properties 92 and therefore does not preferentially target Cav2.2 channels in hyperactive neurons. Several small organic Cav2.2 channel inhibitors, however, have been shown to mediate strong use-dependent inhibition of Cav2.2 channels in the nanomolar range. This includes Z160 (also known as NMED-160 or NP-118809; Epirus), a compound that mediates potent analgesia in several animal models of pain 93 . Unfortunately (and very much surprisingly) this compound failed two different Phase II clinical trials for lack of efficacy, for reasons that are unclear. Other state-dependent Cav2.2 channel blockers that are currently in preclinical development include compounds such as TROX-1 (Merck) 94 and CNV2197944 (Convergence Pharmaceuticals, now held by its sister company Calchan Ltd), which has successfully completed Phase I clinical trials and is now in Phase II trials for postherpetic neuralgia and painful diabetic neuropathy (see the Convergence Pharmaceuticals press release for further information). Several other classes of small organic Cav2.2 channel blockers with efficacy in animal models of pain have been reported in the literature (see , some of which also target T-type calcium channels 100 . This latter point is pertinent, as T-type calcium channels are also emerging as suitable targets for analgesics. Following early studies showing that intrathecal delivery of the T-type channel inhibitor ethosuximide (Zarontin; Pfizer) mediates analgesia 101 , it was shown that intrathecal delivery of small interfering RNA (siRNA) against Cav3.2 channels, but not other T-type calcium channel isoforms, protected against inflammatory and neuropathic pain 102 . This led to the discovery of a number of different scaffolds for high affinity T-type calcium channel inhibitors with efficacy in a variety of pain models after either subdural or systemic (intra peritoneal) delivery [103] [104] [105] [106] [107] [108] . Notably, this included a novel class of dihydropyridine blockers that preferentially inhibited Cav3.2 channels over L-type channels, as well as several compounds that were derived from cannabinoid receptor ligands. This is in accordance with the observation that endocannabinoids such as anandamide have been found to potently block T-type channels 109, 110 . A mixed blocker of Cav3 and Nav1.7 sodium channels, Z123212, has been described as a potent analgesic in rodents 111 . This compound interacts preferentially with the slow inactivated state of these channels, thereby giving rise to strong use-dependent inhibition. Although most of these compounds are still in preclinical development, Z944 (Epirus Pharmaceuticals) 112 , a potent and statedependent T-type calcium channel inhibitor, completed Phase I clinical trials for pain and is being advanced to Phase II trials. It remains to be determined whether the analgesic actions of T-type channel inhibitors occur via inhibition of synaptic activity in the dorsal horn, or Harmful stimuli (such as pressure, heat and cold) are detected by nerve endings embedded in the skin or organs, leading to the generation of action potentials that travel along the afferent fibre to synaptic terminals in the spinal dorsal horn, where neurotransmitter release activates postsynaptic neurons that project to the brain. Cav3.2 calcium channels regulate afferent fibre excitability and contribute to calcium influx in synaptic nerve terminals. Cav2.2 channels are located presynaptically where their opening allows calcium entry and leads to neurotransmitter release. CNS, central nervous system.
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by alterations of afferent fibre excitability 74 . Interestingly, a small randomized trial evaluating the Cav3.2 channel blocker ABT-639 (AbbVie) as a therapeutic for diabetic pain revealed a lack of efficacy compared to placebo 113 . This does not, however, invalidate the potential of T-type calcium channel inhibitors as analgesics.
Finally, there is emerging evidence that Cav2.3 (R-type) calcium channels may be involved in pain signalling. Intrathecal delivery of the Cav2.3 inhibitor SNX-482 (a peptide derived from the venom of a Tarantula species) inhibits formalin-induced pain and neuropathic pain in rodents 114, 115 . This is consistent with the expression of these channels in dorsal root ganglion (DRG) neurons and in the spinal dorsal horn 116 , as well as with data showing that Cav2.3-null mice display pain hyposensitivity 117 . However, it should be noted that this compound also inhibits L-type calcium channels, albeit at higher concentrations than those needed for Cav2.3 channel block 118 . Polymorphisms in the gene encoding Cav2.3 have been linked to changes in fentanyl sensitivity in patients undergoing surgery 119 , altogether suggesting that Cav2.3 calcium channels could be explored as potential targets for pain. There is currently no selective small organic inhibitor of Cav2.3 channels, although it should be noted that the N-type channel blocker TROX-1 also mediates inhibition of Cav2.3 channels with about 50% lower affinity compared with Cav2.2 channels (REF. 94 ). This compound could thus perhaps form the starting point for the development of a preferential Cav2.3 inhibitor.
Calcium channels as targets for seizure disorders Seizures occur as a result of a combination of hyperexcitability and abnormal synchrony of neurons. Focal seizures typically involve one hemisphere and can arise from injury to a specific brain structure or from a tumour 120 . Conversely, idiopathic seizures are not accompanied by radiological abnormalities, typically involve both hemispheres and can be triggered by more diffuse insults to the brain, such as high fever (that is, febrile seizures), hypoxia, or even oxygen toxicity 121 . They may also arise from genetic abnormalities in a variety of ion channels and receptors, such as voltagegated sodium channels and GABA receptors [122] [123] [124] . Absence seizures are one of the hallmarks of idiopathic generalized epilepsy (IGE) and are characterized by brief periods of unresponsiveness and abnormal spike and wave discharges in EEG recordings that reflect hypersynchronous activity of thalamocortical structures 125 . It is thought that the initiation of absence seizures is critically dependent on the activation of T-type calcium channels in thalamocortical neurons and reticular thalamic nucleus neurons (nRT neurons) 126 , which express Cav3.1 and Cav3.2/Cav3.3 calcium channels, respectively (FIG. 3a) . The firing of these neurons can be drastically altered by even small changes in T-type channel activity 127 . Furthermore, in several genetic mouse models of absence epilepsy (such as Cav2.1-knockout mice, 'lethargic mice' that lack functional Cavβ4, and 'stargazer mice' , which carry a loss-of-function mutation in the Cavγ2 subunit), there is an increase in T-type calcium channel activity in nRT neurons 128 . Along these lines, in the GAERS rat model of absence epilepsy, there is an increase in thalamic T-type channel activity (which is accompanied by increased Cav3.2 mRNA levels) owing to a gain-offunction mutation in Cav3.2 (REF. 129 ). Interestingly, this gain-of-function mutation is only able to manifest functional changes in a specific Cav3.2 splice isoform that contains exon 25 (which is the predominant splice isoform expressed in the thalamus) 129 .
A subset of these mutations was shown to mediate a gain of function in channel gating, with some of the mutations promoting plasma membrane trafficking of the channels [131] [132] [133] (FIG. 3b) . These gain-of-function effects may not only affect the electrical excitability of neurons but also alter gene transcription events 134 . Given the findings with the GAERS model, it is important to consider the specific splice variant background that is used for such functional studies, such that they accurately reflect their physiological effects. Cav3.1-overexpressing mice show enhanced thalamocortical network activity and present with pure absence seizures 135 . Altogether, these findings indicate that enhanced activity or expression of T-type calcium channels in the thalamus increases seizure susceptibility. It thus stands to reason that decreasing the activity or expression of these channels should protect against seizures. Indeed, mice lacking Cav3.1 calcium channels are resistant to baclofen-induced seizures 136 . Furthermore, when crossed with Cav3.1-knockout mice, the seizure abnormalities in several mouse models of absence epilepsy are normalized 128 . Overall, these findings support the idea that targeting Cav3.1 and Cav3.2 channels could be a strategy for mitigating absence seizures.
The role of Cav3.3 channels in the generation of burst firing in nRT neurons is somewhat controversial. On the one hand, Cav3.3 channel activity can give rise to bursting behaviour that fits with that observed in nRT neurons 137 , and this appears to be a critical factor in the generation of sleep spindles 138 . On the other hand, mice that either globally lack Cav3.3 channels, or mice that are selectively deficient for Cav3.3 channels in nRT neurons, appear to show greater susceptibility to pharmaco logically induced spike and wave discharges and increased inhibitory synaptic inputs onto thalamocortical neurons 139 . It is currently not clear whether knockout of Cav3.3 could lead to compensatory increases in the expression of other ion channels or receptors that lead to such an increase in the excitability of nRT neurons. Furthermore, owing to the lack of selective Cav3.3 channel blockers, it is not clear whether acute inhibition of these channels mediates effects that 
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An anti-epileptic drug with multiple molecular targets.
are equivalent to those observed upon deletion of the gene encoding Cav3.3. Nonetheless, when developing T-type calcium channel blockers for therapeutic intervention, this ambiguous role of Cav3.3 channels should be considered.
Ethosuximide is a T-type calcium channel blocker that has been used clinically to treat absence seizures 140 . This compound is a low-affinity (in the submillimolar range) blocker of all three Cav3 channel isoforms, with a preference for inactivated channels, and it gives rise to use-dependent inhibition 141 . The anti-epileptic sodium valproate (Depakene/Convulex; Abbott) has also been described as a T-type channel inhibitor 142 . However, this compound is also known to inhibit other targets such as sodium channels 143 and histone deacetylases 144 . Along these lines, the multitarget antiepileptic drug zonisamide (Zonegran; Eisai) has also been reported to inhibit T-type channels in the micromolar range, but curiously without any apparent state dependence 145 . Interestingly, there is evidence that this compound also improves pain responses in rodents, further supporting the role of T-type channels in pain signalling (as discussed in the section above) 146 . More recent drug discovery efforts by Zalicus (now Epirus Biopharmaceuticals) have identified small organic molecules (including the aforementioned compound Z944 and a compound termed Z941) that potently inhibit Cav3.2 T-type calcium channels and block seizure activity in the GAERS model 147 . Z944 was also shown to inhibit burst firing in nRT neurons, which is consistent with the critical role of these channels in thalamic neuron excitability. As Z944 is already in clinical testing for pain, this may provide the opportunity for testing this compound in patients with absence seizures.
HVA calcium channels may also be targeted for the treatment of seizures. Gabapentin is used as an anticonvulsant to treat focal and partial seizures 148 . However, given that this compound has the propensity to affect multiple types of HVA channels through its interaction with Cavα2δ subunits, it is not clear how this compound mediates its clinical effects at the cellular level. The anti-epileptic lamotrigine (Lamictal; GlaxoSmithKline) is also widely used for the treatment of focal and absence seizures, but its mode of action remains incompletely understood 149, 150 . This compound blocks transiently expressed R-type Cav2.3 channels in the low micromolar range, with a small effect on Cav3.1 channels 151 . A recent study revealed that the anti-seizure effects of lamotrigine observed in mice are dependent Descending excitatory projections innervate nRT neurons and TCNs, whereas nRT neurons have inhibitory inputs onto thalamocortical cells. The excitability of this network is strongly dependent on T-type calcium channels, with Cav3.1 channels being expressed in TCNs, and Cav3.2 and Cav3.3 channels being expressed in nRT neurons. b | Mutations in Cav3.2 that are found in patients with congenital forms of absence epilepsy increase Cav3.2 channel function. The C456S mutation increases cell surface expression of the channels, whereas the V831M mutation increases channel availability by mediating a depolarizing shift in the steady-state inactivation curve. Both cases result in increased T-type current amplitudes, leading to increased excitability of nRT neurons and thus absence seizures.
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on the presence of Cav2.3 channels 152 . Specifically, lamotrigine protected from kainate-induced seizures in wild-type mice but not in Cav2.3-null mice, where this compound in fact mediated a paradoxical increase in seizure activity that remains to be explained 152 . Similar observations were made with topiramate (Topamax; Mylan) 152 , an anticonvulsant that targets multiple types of channels and receptors, including R-type channels that are blocked in a state-dependent manner, with an IC 50 (half-maximal inhibitory concentration) of around 50 mM 153 . Although it is not clear to what extent the clinical actions of these compounds are mediated by Cav2.3 channel inhibition, the notion that Cav2.3 channels share overlapping biophysical properties with members of the Cav3 channel family fits with such a possibility. Finally, a recent study reported that Cav1.2 channels in pyramidal cells activate at relatively hyperpolarized potentials when the temperature is increased to 40 °C, thereby allowing these channels to drive intrinsic firing properties 154 . The authors hypothesized that this effect could contribute to the development of febrile seizures. In support of this hypothesis, nimodipine (Nimotop; Bayer) blocked the development of temperature-induced seizures in rat pups 154 , suggesting that dihydropyridines could be explored as a treatment option. However, nimodipine is known to weakly inhibit T-type calcium channels 155 , and hence it remains to be determined whether this compound inhibited febrile seizures by blocking L-type channels, T-type channels, or perhaps both.
Overall, voltage-gated calcium channels provide potential targets for both idiopathic and focal seizures, with T-type calcium channels perhaps being the most promising candidates among the calcium channel family. However, given that there are already about two dozen medications on the market that can be used to control seizures 156 , there has been a relative lack of new drug discovery efforts in the pharmaceutical sector.
Calcium channel blockers in Parkinson disease
Parkinson disease is one of the most common neurodegenerative disorders with a characteristic loss of dopaminergic neurons in the substantia nigra pars compacta; along with the loss of dopaminergic neurons in the striatum, which leads to a progressive impairment in motor skills, the occurrence of tremor 157 and other comorbidities such as the development of psychosis 158 . Motor symptoms such as tremor are treated with a range of drugs, including anticholinergic agents, beta blockers and dopamine receptor agonists 159 , but current options for preventing the loss of dopaminergic neurons remain insufficient. It is well known that neurons from patients with Parkinson disease exhibit inclusion bodies formed by α-synuclein 160 , although it remains unclear whether these inclusion bodies are causal to neuronal degeneration. Several genes have been implicated in the development of familial Parkinson disease, including Parkin, α-synuclein, leucine-rich repeat serine/threonine protein kinase 2 (LRRK2) and PTEN-induced putative kinase 1 (PINK1) 161 , and many of these genes affect mitochondrial or lysosomal function 162 . Despite many advances, the cellular and molecular basis of this selective neuronal loss remains to be fully understood, and this in turn has hampered the discovery of a cure for this disorder. One possible mechanism that has been implicated in neuronal loss during Parkinson disease involves L-type Cav1.3 calcium channels. These channels can modulate pacemaking of substantia nigra neurons owing to their hyperpolarized range of voltage-dependent activation 163 , although they do not appear to be critical for the pacemaking process per se 164 . Indeed, earlier work showing that dihydropyridines could alter the pacemaking properties of substantia nigra neurons 165 may have been related to their off-target effects on other ion channels 164 . Nonetheless, the repetitive opening of Cav1.3 channels (and possibly also Cav1.2 channels) during pacemaking may contribute to excessive calcium entry that in turn causes cytotoxicity though mitochondrial stress 166 (FIG. 4) . It is also interesting to note that in human brains from patients with earlystage Parkinson disease, expression of Cav1.3 channels is increased, supporting a possible causal role of these channels in disease pathology 167 . A recent study identified an additional role of Cav1.3 channels in Parkinson disease 168 . Calcium influx via Cav1.3 channels was shown to trigger a neuronal calcium sensor 1 (NCS1; also known as FLUP)-dependent enhancement of the activity of dopamine D2 autoreceptors (which are known to contribute to pathogenesis by virtue of their ability to regulate pacemaker activity) and loss of receptor desensitization 168, 169 (FIG. 4) .
This, in turn, would then be expected to contribute to a pathologically relevant dysregulation of dopamine neuron function. Hence, Cav1.3 channel activity may contribute to Parkinson disease pathology by multiple mechanisms, and therefore Cav1.3 channel-selective inhibitors could be a potential therapeutic strategy. Indeed, a Phase II clinical trial evaluating the safety of isradipine (Dynacirc; Reliant) as a potential Parkinson drug has been completed with promising results 170 . This clinical study evaluated the safety, tolerability and efficacy of isradipine in patients with early symptoms of Parkinson disease that did not yet require treatment with dopamine receptor agonists. Results showed that the drug was tolerated in a dose-dependent manner, with an optimal dose determined at 10 mg daily. Side effects at higher doses included the development of oedema and dizziness. A large Phase III trial is currently underway at Northwestern University, Illinois, USA. It is also important to note that there is evidence that patients on dihydropyridine antihypertensives show a reduced risk of developing Parkinson disease when compared to either patients who are not on such regimens or patients who are treated with types of antihypertensives that do not cross the blood-brain barrier 
Nucleus accumbens
A specific brain region that is involved in reward behaviour. study reported lower blocking affinities and weaker channel subtype selectivity of this compound compared to those reported earlier 173 . However, the blocking effects were also shown to vary with the Cavβ subunit that was co-expressed and with the particular Cav1.3 channel splice isoform that was used 173 . Finally, yet another study reported that this compound in fact increased Cav1.3 channel activity by affecting channel gating in a complex manner, with inhibition only being observed when barium was used as a charge carrier 174 . Although the reason for these discordant observations remains unclear, one possibility may be the use of different Cav1.3 channel splice isoforms in these pharmacological tests on transiently expressed channels. Irrespective of these discrepancies in the literature, the general premise of targeting Cav1.3 channels for preventing the dopaminergic neuron loss observed in Parkinson disease remains valid.
Finally, it should be noted that T-type calcium channels have recently been implicated as a potential target for treating motor abnormalities in Parkinson disease. In a rat model, T-type calcium channel inhibitors such as mibefradil (now withdrawn from the market) and NNC-55-0396 blocked burst firing activity in slices of the subthalamic nucleus, a brain structure that is known to exhibit increased bursting activity during Parkinson disease 175 . Furthermore, locomotor deficits in a rat model of Parkinson disease were reduced by these compounds 175 . Hence, it will be interesting to determine whether new T-type channel blockers such as Z944 may show efficacy in patients with Parkinson disease.
Role of calcium channels in drug dependency
Drug dependency can be considered a chronic disease in which affected individuals experience the compelling need to consume substances of abuse, and this is a major contributor to mortality 176, 177 . These substances include both legal drugs such as alcohol and nicotine, as well as prohibited substances such as cocaine. Dependency involves long-term changes to the brain architecture 178 that predispose individuals to relapse even after very long periods of abstinence, and these may differ from brain circuits that are involved in the immediate reward associated with psychostimulants 179, 180 . The cellular and molecular mechanisms underlying dependency are highly complex and multifaceted. The key brain structure that is involved in the development of dependency is the mesolimbic system 181 , in particular the dopaminergic projections from the ventral tegmental area to the nucleus accumbens and its outputs 182 (FIG. 5) . Even though different types of addictive substances may act at different receptors (for example, morphine activates μ-opioid receptors and nicotine activates nicotinic acetylcholine receptors), they all lead to an overall increase in dopamine levels in the mesolimbic system 183 and altered cAMP response element binding protein (CREB)-dependent gene expression in the ventral tegmental area and nucleus accumbens 184 . For over two decades, L-type channels have been known to have a role in this process 185 , as compounds such as nimodipine (Nimotop; Bayer) and diltiazem (Cardizem; Biovail) block behavioural sensitization to cocaine 186, 187 and attenuate alcohol intake 188 . The Cav1.3 calcium channel subtype appears to contribute to the amphetamine-induced upregulation of dopamine receptor mRNA in the ventral tegmental area 189 and is essential for behavioural sensitization in response to cocaine and amphetamines 190 . After pre-exposure to cocaine, Cav1.2 channels are upregulated in the nucleus accumbens, which in turn causes long-term changes in gene expression and a phosphorylation-dependent insertion of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors into the plasma membrane, which gives rise to longterm plasticity 190, 191 (FIG. 5) . This process depends on the activation of Cav1.3 channels in the ventral tegmental area 192 , presumably via the release of dopamine and activation of D1 receptors. This plasticity is maintained after cocaine withdrawal. Conversely, in the dorsal striatum, long-term cocaine exposure causes a decrease in AMPA receptor phosphorylation or insertion that depends on the activation of D2 receptors and Cav1.3 channels, but not on those that are expressed in the ventral tegmental area 191 . Furthermore, during chronic methamphetamine treatment, there is an increase in Cav1.2 mRNA expression in ventral tegmental area neurons, which may also contribute to long-term changes in gene expression 189, 193 . A subsequent study revealed that Cav1.2 and Cav1.3 channels mediate distinct neuronal firing patterns in ventral tegmental area neurons, with Cav1.3 channels driving both single spike and burst firing, whereas Cav1.2 channels are mainly important for bursting behaviour 194 (FIG. 5) . This, in turn, suggests that these two channel types differentially contribute to dopaminergic modulation of the nucleus accumbens.
Altogether, a picture emerges in which Cav1.3 channels are crucial mediators of plastic changes in the mesolimbic system in response to psychostimulants, which then lead to a longer form of plasticity in the nucleus accumbens that is dependent on the Cav1.2 channel. The latter may perhaps contribute to the long-term structural changes that predispose individuals to relapse after abstinence. This therefore suggests that L-type calcium channel blockers could prove beneficial in the treatment of addiction. Indeed, there is evidence from human studies that this may be the case 195, 196 . For example, L-type calcium channel inhibitors such as nifedipine (Procardia/Adalat; Pfizer/Bayer) Figure 5 | Role of L-type calcium channels in drug addiction. Simplified neuronal circuitry involved in addiction is shown. Dopaminergic neurons in the ventral tegmental area (VTA) project to both the nucleus accumbens (NAc) and the prefrontal cortex (PFC). The NAc is a major output nucleus for reward-seeking behaviour and has both direct and indirect (not shown) projections back to the VTA. Chronic exposure to psychostimulants activates Cav1.3 channels and increases dopamine release from the VTA, which in turn stimulates glutamatergic inputs. Glutamate activates AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and NMDA (N-methyl-d-aspartate) receptors (GluR) on VTA neurons, and together with Cav1.3 channel activity it leads to changes in gene expression that include the upregulation of Cav1.2 calcium channels. Cav1.2 and Cav1.3 channels differentially regulate the firing behaviour of VTA neurons, which in turn drives dopamine release in the NAc. There, activation of dopamine D1 receptors (D1Rs) activates protein kinase A (PKA), which, together with an upregulation of Cav1.2 channels, mediates long-term changes in gene expression and AMPA receptor insertion into the plasma membrane. CamKII, calcium/calmodulin-dependent protein kinase II; CREB, cAMP response element binding protein; ERK, extracellular signal-regulated kinase; GluR, glutamate receptor.
Cilnidipine
A specific dihydropyridine that blocks both N-type and L-type calcium channels.
Bipolar disorder
A neuropsychiatric condition marked by alternating bouts of elation and depression.
Schizophrenia
A common neuropsychiatric disorder.
Amygdala
A specific brain region known to be involved in fear.
and verapamil (Calan; Pfizer) have been shown to reduce withdrawal symptoms from a number of addictive substances, including opiates and ethanol 195, 196 . It remains to be determined whether these effects in humans are dependent on the activity of Cav1.3, Cav1.2, or both types of channels. Such knowledge could potentially guide future therapeutic strategies in this setting.
In addition to L-type calcium channels, blockers of other types of calcium channels may also be a useful strategy. A mixed N-type/T-type calcium channel blocker (NMED-126; also known as NP078585) was shown to reduce alcohol intoxication in mice, as well as alcohol self-administration and reinstatement 197 . The effects of this compound were absent in Cav2.2-knockout mice, indicating that it acted predominantly via N-type rather than T-type channel inhibition. Whether these effects occur at the network level in the mesolimbic system is not known; nonetheless, these data point to a potential strategy of using mixed N-type/L-type channel inhibitors to target drug and alcohol dependency. One such blocker that is used currently in the clinic is cilnidipine (Atelec/ Cilacar; Fuji/Ajinomoto), an antihypertensive from the dihydropyridine class 70 . Importantly, this compound suppresses ethanol-induced locomotor sensitization in rats 198 .
Calcium channels and psychiatric disorders Several calcium channel genes have been associated with the development of psychiatric symptoms. Singlenucleotide polymorphisms in intron sequences in the gene encoding Cav1.2 (in particular, a risk locus termed rs1006737) and in the Cavβ2 subunit have been associated with an increased risk of bipolar disorder and schizophrenia 199, 200 . Importantly, healthy individuals carrying the CACNA1C rs1006737 risk variant show compromised function of the anterior cingulate cortex, prefrontal cortex and hippocampus in functional magnetic resonance imaging (MRI) studies [201] [202] [203] . A subsequent study identified Cav1.3 as another possible risk gene for bipolar disorder, with a lower degree of association for Cav2.2 and Cav3.1 (REF. 204 ). It was concluded that these channels and other types of ionic channels share a common role in regulating neuronal excitability; however, this may be an overly simplistic view as these channels have highly specialized roles that can differ across brain regions 7 . How polymorphisms in intronic sequences of Cav1.2 may contribute to an increased risk of schizo phrenia is not yet understood. It is possible that they could lead to altered expression of Cav1.2 channels 205 , and this would be consistent with a recent report showing higher Cav1.2 activity in induced neurons from carriers of the polymorphism 206 . Nonetheless, the association of bipolar disorders with two different types of L-type calcium channels suggests that L-type calcium channel blockers are a possible treatment avenue. Indeed, a preliminary clinical study on the use of isradipine for the treatment of bipolar disorder yielded promising results 207 , but this needs to be followed up with larger cohort studies.
Gain-of-function mutations in Cav1.2 that interfere with the normal voltage-dependent inactivation mechanisms in these channels have been associated with Timothy syndrome, a severe condition that includes fatal cardiac arrhythmias, developmental abnormalities and autism 208, 209 . This change in channel function not only affects the electrophysiological properties of excitable cells but, as evident from studies on neuronal progenitor cells from patients with Timothy syndrome, also leads to massive alterations in gene transcription 210 and enhanced dendritic retraction 211 . An autistic phenotype is also observed in human patients with gain-offunction mutations in Cav1.3 channels 212 . Furthermore, rare mutations in the Cavβ2 subunit in families with autism spectrum disorder lead to slowed L-type calcium channel inactivation kinetics 213 . This raises the possibility that L-type calcium channel inhibitors or, more specifically, L-type channel inactivation enhancers, could be used as treatments for certain types of autism. However, so far there have been no clinical trials to test this hypothesis. It is also noteworthy that single-nucleotide polymorphisms in all three Cav3 channel isoforms have been associated with autism 214 . In the case of Cav3.2, such mutations have been shown to cause a loss of function 215 . To what extent Cav3 channels can be exploited as potential targets for autism remains to be determined.
Anxiety disorders are another group of highly prevalent psychiatric conditions that may involve voltage-gated calcium channels. Anxiety can be defined as an apprehensive reaction to a non-threatening stimulus, and it is thus not surprising that the neural circuitry that is involved in anxiety is intimately tied to that of fear 216, 217 , which encompasses the amygdala, the nucleus accumbens and the hippocampus 218 . Optogenetics-based studies have revealed that inputs from the amygdala to the hippocampus are essential for the development of anxiety-related behaviours 219 . A recent study reported an increase in the expression of the Cavα2δ1 subunit in the amygdala in a rat model of chemically induced anxiety 220 . Notably, pregabalin reversed the anxiety phenotype, which fits with ample clinical data showing that both gabapentin and pregabalin are effective in treating anxi ety disorders in humans 221 . The upregulation of Cavαδ subunits appears to be accompanied by an increase in the expression of Cav1.2 and Cav1.3 calcium channels 222 . Along these lines, there is an increase in the expression of Cav1.2 calcium channels in fear-conditioned rats 222 . In these experiments, nimodipine was shown to block startle responses 222 . Although these findings raise the possibility of testing L-type calcium channel inhibitors as potential anxiolytics, deletion of Cav1.2 channels in the forebrain appears to give rise to an anxiety phenotype in mice 223 , as does haploinsufficiency of Cav1.2 channels in female mice 224 . Moreover, higher doses of nifedipine and verapamil have been shown to exert anxiogenic effects in mice 225 . Conversely, there are weak indications that Cav1.3 deficiency may have anxiolytic effects 226 . Therefore, it is currently unclear whether L-type channels may serve as targets for anxiety disorders and how they modulate the underlying neuronal circuitry.
It is important to note that N-type channels may also have a role in the development of anxiety dis orders, as mice lacking Cav2.2 display reduced levels of anxiety 227 . It is conceivable that the aforementioned anxiolytic effects of gabapentin could be due to a Cavα2δ-dependent effect on Cav2.2 channels 228 . Finally, mice lacking the Cavβ3 subunit show reduced anxiety along with increased aggression 229 , and it is possible that this is due to reduced expression of Cav2.2 channels arising from the absence of this important auxiliary subunit.
Overall, there is evidence supporting the utility of voltage-gated calcium channel blockers in a variety of psychiatric disorders. What remains to be understood in greater depth is how individual calcium channel isoforms contribute to the development of such conditions at the neuronal network level.
Challenges and opportunities
The importance of voltage-gated calcium channels as drug targets for nervous system disorders has been clearly established. As there are already clinically approved inhibitors of N-, L-and T-type calcium channels, this may allow the rapid testing of these existing drugs in a wide range of neurological conditions, as exemplified by the use of the antihypertensive isradipine as a potential intervention for Parkinson disease 170 . Furthermore, as calcium channels have important roles in many other physiological processes, such as the regulation of sleep patterns 138, 230 and food intake 231 , the palette of possible therapeutic applications of calcium channel inhibitors may well increase to include conditions such as insomnia and eating disorders, among others. Nonetheless, there remains a pressing need for new calcium channel blockers, especially for conditions such as neuropathic and inflammatory pain, which are often refractory to treatment. In particular, to minimize side effects, it is important to develop new types of calcium channel inhibitors that specifically target the calcium channels that are involved in pathophysiological processes, while sparing those that contribute to normal physiological function. This requires an in-depth understanding of how calcium channels partake in the function of specific brain circuits that are implicated in pathophysiology and how these channels may be dysregulated in pathological states.
First, it is important to know the precise molecular architecture of the channels expressed in these neurons, which, as noted earlier in this article, may guide drug discovery strategies. For example, it has been shown that Cav2.2 calcium channels in pain-sensing neurons contain exon 37a rather than exon 37b, which is more widely expressed in the nervous system 232 and that the exon37a variant is critical for pain signalling 233 . If one were to develop an inhibitor that selectively targets exon37a-containing channels, then the potential of CNS side effects may be reduced. Along these lines, it is possible that calcium channels undergo age-dependent alternative splicing events (this has been demonstrated at least for P/Q-type channels) 234 , and this could potentially be relevant for the pathogenic role of Cav1.3 calcium channels in Parkinson disease. In the context of ageing, matters are further complicated by the fact that Cav1.2 channels undergo an age-dependent form of proteo lysis in the plasma membrane that results in the generation of functional channels with altered biophysical characteristics 235 .
Besides modification of the pore-forming channel subunit per se, knowledge of the association of the calcium channel Cavα1 subunits with specific ancillary subunits and the interactions of calcium channels with other regulatory elements, may be important considerations for drug development. For example, Cav1.3 channels in cochlear hair cells associate with calcium-binding proteins such as CaBP2 and CaBP4, which changes the biophysical and perhaps the pharmaco logical characteristics of these channels 236, 237 . When designing Cav1.3 channel inhibitors for the treatment of conditions such as Parkinson disease or addiction, it may thus prove advantageous to select compounds with lower affinity for channels that are complexed with CaBP2, in order to avoid the possibility of drug-induced hearing deficiencies. This could be accomplished by screening compounds against cell lines that stably co-express CaBP2 and Cav1.3 channels.
Second, it is important to understand the intrinsic firing properties of the neuronal circuits that are involved in pathological states. For example, hyperexcitability disorders such as epilepsy may call for calcium channel blockers that are strongly use-dependent. This strategy has been successfully exploited with anti-arrhythmic and anticonvulsant drugs and, as noted above, it is possible to identify these types of compounds with new drug screening technologies 238 . Indeed, several of the newer T-type calcium channel blockers such as Z944 exhibit this feature, as does the N-type channel inhibitor TROX-1. In other cases, it may prove advantageous to develop tonic blockers of a particular calcium channel subtype. Third, it may be possible to target aberrant upregulation of calcium channels, as seen in pain-sensing neurons after injury. Indeed, such an approach has been demonstrated for the interactions between Cav2.2 channels and collapsin response mediator protein 2 (CRMP2; also known as DRP2), which promotes stability of the channel complex in the plasma membrane 239 . Uncoupling of CRMP2 from the channel via disruptor peptides reduces calcium currents and mediates analgesia 239 . Along these lines, interactions between Cav3.2 calcium channels and the deubiquitinase ubiquitin-specific processing protease 5 (USP5) have been shown to promote enhanced channel expression in the plasma membrane in a range of chronic pain conditions 240 . Disruptor peptides that interfered with the association of the two proteins prevented this aberrant upregulation, thereby mediating analgesia. Importantly, small organic mimetics of these peptides that were identified in an enzyme-linked immunosorbent assay (ELISA) screen prevented the USP5-Cav3.2 interaction in vitro and blocked the development of pain hypersensitivity in several different animal models 241 . This is an example in which targeting a protein-protein interaction can be exploited towards therapeutic indications. Because such protein-protein interactions often occur in intracellular regions in which there is greater sequence divergence among various calcium channel isoforms, this approach has the potential to achieve greater target selectivity. Furthermore, by targeting an association that occurs in a pathophysiological state and not under normal physiological conditions, the potential of interfering with normal physiology (and thus the possibility of side effects) is minimized.
Finally, knowledge of how mutations in calcium channel genes alter channel function can be exploited towards the development of therapeutics. This is exemplified by a recent study in which a gain-of-function mutation in Cav2.1 causing familial hemiplegic migraine was introduced into Drosophila melanogaster and shown to alter synaptic physiology at the neuromuscular junction 242 . A compound (ter-butyl dihydroquinone) that is able to offset the enhancement of channel function to normalize the synaptic defects associated with the mutation was then applied, thus restoring normal synaptic physiology. Although such a targeted approach has not been described for treating calcium channelopathies in humans, it has been successfully applied to patients with erythromelalgia who have gain-of-function mutations in Nav1.7 sodium channels 243 . It may thus be possible to adopt similar strategies for gain-of-function calcium channelopathies such as absence epilepsy, migraine or Timothy syndrome.
Altogether, there remains tremendous untapped potential towards the design of new calcium channel blockers for the precise (and perhaps personalized) targeting of a wide range of neurophysiological and psychiatric conditions. The above considerations underscore the need for fundamental insights into the roles of calcium channels in nervous system function at the cellular, molecular and network level. With many of the large pharmaceutical companies reducing in-house discovery efforts, this important task may need to fall on the academic community.
Channelopathies A group of conditions in which mutations in specific ion channels give rise to disease.
